Oncolytics Biotech Inc ONCY

Biotech industry readies for " Pharma M&A Spree"

[Noteable]

November 16, 2024 - "Biotechnology and big pharma are noteworthy. Pharma needs biotech for new products, so M&A benefits both—securing revenue for pharma and providing premium buyouts for biotech.

Overall, the innovative drug space, especially biotech, may see a significant boost due to anticipated M&A."

https://www.paidpromotionalmessages.co.uk/companies/news/1060741/trump-s-win-can-spark-pharma-m-a-spree-suggests-bellevue-healthcare-icymi-1060741.html

https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=34876203

[Noteable]

So what does that mean? The push to plug patent-loss gaps has left fewer late-stage biotechs available for Big Pharma to scoop up, so there are more deals around earlier-stage companies and assets. The result is that these late-stage biotech companies and assets will be acquired at significant M&A premiums, from where they may currently trade. As we know, ONCY is a late-stage clinical

[Noteable]

Furthermore, a Republican administration may be friendlier to large deals and may focus its drug pricing bite on PBMs rather than on pharma's deal-making activities.

[Noteable]

With the appointment of John Hopkins pancreatic surgeon Dr. Marty Makary to the position of FDA Commissioner-elect , a Republican administration may be friendlier to large deals particularly for late-stage biotech companies with biologic drug platforms that are targeting diseases with unmet medical treatment needs, like ONCY's pelareorep is focused on, and may focus its drug pricing

[Noteable]

November 25, 2024 - Pfizer’s sales surge in Q3. In the third quarter, part of Pfizer’s revenue increase (PDF) from $13.2 billion to $17.7 billion could be attributed to its acquisition of Seagen and the $854 million in additional sales brought by products from the Seattle cancer specialist. https://www.fiercepharma.com/pharma/while-lilly-and-novos-momentum-stalled-q3-pfizer-moved

[Noteable]

The recent push to plug patent-loss gaps by Big Pharma has left fewer late-stage biotechs available for Big Pharma to scoop up, so there are more deals around earlier-stage companies and assets. The result is that these late-stage biotech companies and assets will be acquired at significant M&A premiums, from where they may currently trade, particularly if those companies and their assets

[Noteable]

November 19, 2024 - For “almost three years now” deal making has been a challenge across the life sciences industry, said Ed Saltman, senior strategic advisor at consultancy firm Lumanity, described to the audience at Bio Europe in Stockholm, Sweden. He outlined three points he believes are the “biggies” to shape the conversation. Number one, “pharma needs to rely on biotech for

[Noteable]

A growing emphasis on using synthetic control arms (SCA), which are derived from historical real-world evidence (RWE) using advanced statistical methods are becoming adopted by the regulatory bodies and CROs, like GCAR, who will be conducting ONCY's Phase 2/3 pancreatic cancer clinical trial.  Implementing an SCA eliminates the need for enrolling placebo groups in certain

[Noteable]

Advanced statistical methods are becoming adopted which preclude the need to "power a study" through sample size and patient enrollment numbers. A growing emphasis on using synthetic control arms (SCA), which are derived from historical real-world evidence (RWE) using advanced statistical methods are becoming adopted by the regulatory bodies and CROs, like GCAR, who will

[Noteable]

According to a new report from Leerink Partners outlining large pharma companies’ loss of exclusivity (LOE) exposure between both 2025 and 2030, and 2030 through 2040, Leerink accounted for 17 large-cap biopharmas who will be significantly affected, and only included drugs with expected revenue of $1 billion or more in the base years of 2025 or 2030. The analyst team omitted antibody-drug

[Noteable]

Bristol Myers Squibb faces the greatest risk of exposure in the near future, with 64% of its estimated revenue in 2025 ($48.3 billion) subject to patent losses and generics through the end of the decade, according to Leerink’s report.  Behind BMS, Merck faces the next greatest threat of exposure from 2025-2030 at 47% of its $72 billion in estimated 2025 revenue, the Leerink team said

[Noteable]

M&A tends to pick up as company’s approach big Loss of Exclusivity (LOE) events. For Merck, they’re facing a $30B LOE in 2028 with Keytruda and have made big bets on Acceleron ($11.5B) cardiovascular platform in 2021 and Prometheus ($10.8B) I/O platform in 2023 + several mid-sized deals are attempts to plug that. AbbVie is a few years ahead, having just gone through this process

[Noteable]

Some bigger deals have been completed this year but none were instances in which a pharma group was buying a biotech to get hold of promising drugs.  A tough antitrust environment under Lina Khan’s Federal Trade Commission as well as the political uncertainty of an election year has also slowed deal activity. But the election of Donald Trump could usher in the return of bigger healthcare tie

[Noteable]

Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. The conversation offers valuable insights into the future of cancer therapies and the dynamic landscape of the biotech industry.He also touches on the significance of strategic partnerships in accelerating

[Noteable]

November 26, 2024 - Roche acquires Phase 1 allogeneic CAR-T therapy company Poseida for US$1.5 Billion. The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will include CAR-T programs for